重组血管生成抑制因子k4k5抑制视网膜新生血管形成的实验研究

目的 观察重组血管生成抑制因子k4k5 (r-k4k5)对视网膜新生血管形成的抑制作用。 方法 将鼠龄为7 d的88只C 57BL/6J幼鼠置于75%浓度的氧环境中连续生活5 d，建立氧诱导的血管增生性视网膜病变幼鼠模型。幼鼠玻璃体腔内分别注射r-k4k5 500 ng(大剂量治疗组)、250 ng(小剂量治疗组) ，对侧眼注射相同体积的平衡盐溶液(balanced salt solution，BSS)作为对照。二磷酸腺苷(adenosine diphosphate,ADP)酶染色法视网膜铺片，了解视网膜血管改变 ；用组织切片观察并计数突破视网膜内界膜的血管内皮细胞细胞核数目，观察r-k4k5对视网膜新生血管形成的抑制情况。 结果 与对照组相比，治疗组视网膜血管分布规则、密度减少；治疗组突破内界膜的内皮细胞细胞核数目明显减少(P<0.001)；而且与小剂量治疗组相比较，大剂量治疗组内皮细胞细胞核数目减少，两组差异有显著性的意义(P<0.001)。组织切片未见视网膜毒性及炎症反应。 结论 r-k4k5可以抑制视网膜新生血管形成，有望成为防治血管增生性视网膜病变的一种有效的方法。 （中华眼底病杂志，2003，19：121-124）

The inhibitory effects of human recombinant vascularization inhibitor k4k5 on retinal neovascularization

ObjectiveTo explore the inhibitory effects of r-k4k5 on retinal neovascularization.MethodsEighty-eight one-week-old C57BL/6J mice were put into the environment with 75% oxygen for 5 days to establish models of vascular proliferation retinopathy. One eye of each mouse received an intravitreal injection of 500 ng of r-k4k5 (large-dosage group) and of 250 ng of r-k4k5(small-dosage group), and the same volume of BSS was injected into the other eye of the mice both in these two groups as a control. The ADPase histochemical staining was used for retinal flatmount to observe changes of retinal vessels. The inhibitory effects of r-k4k5 on retinal neovascularization were evaluated by counting the endotheliocyte nuclei of new vessels extending from retina to vitreous in the tissue-slice.ResultsRegular distributions and reduced density of retinal blood vessels in eyes in the treatment group were found in retinal flatmount. The number of the endotheliocyte nuclei of new vessels extending from retina to vitreous was less in the eyes in the treatment group than which in control group (P<0.001). The nuclei of new blood vessels in the large-dosage group were less than which in small-dosage group (P<0.001). No histologic evidence of retinal toxicity or inflammatory response was found in the tissue-slice after the injection of r-k4k5.ConclusionsRetinal neovascularization can be inhibited by intravitreal injection of r-k4k5,which suggests that intravitreal injection of r-k4k5 may have potential therapeutic benifits in retinal vascular disease.